DE60222422D1 - Mutationen in ionenkanälen - Google Patents

Mutationen in ionenkanälen

Info

Publication number
DE60222422D1
DE60222422D1 DE60222422T DE60222422T DE60222422D1 DE 60222422 D1 DE60222422 D1 DE 60222422D1 DE 60222422 T DE60222422 T DE 60222422T DE 60222422 T DE60222422 T DE 60222422T DE 60222422 D1 DE60222422 D1 DE 60222422D1
Authority
DE
Germany
Prior art keywords
subject
mutations
ion channels
ion channel
undergone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60222422T
Other languages
English (en)
Inventor
John Charles Mulley
Louise Anne Harkin
Leanne Michelle Dibbens
Hilary Anne Phillips
Sarah Elizabeth Heron
Samuel Frank Berkovic
Ingrid Eileen Scheffer
Robyn Wallace
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionomics Ltd
Original Assignee
Bionomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR6452A external-priority patent/AUPR645201A0/en
Priority claimed from AUPS0910A external-priority patent/AUPS091002A0/en
Priority claimed from AUPS2292A external-priority patent/AUPS229202A0/en
Application filed by Bionomics Ltd filed Critical Bionomics Ltd
Application granted granted Critical
Publication of DE60222422D1 publication Critical patent/DE60222422D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
DE60222422T 2001-07-18 2002-07-08 Mutationen in ionenkanälen Expired - Lifetime DE60222422D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPR6452A AUPR645201A0 (en) 2001-07-18 2001-07-18 Mutations in ion channels
AUPS0910A AUPS091002A0 (en) 2002-03-05 2002-03-05 Mutations in ion channels
AUPS2292A AUPS229202A0 (en) 2002-05-13 2002-05-13 Novel mutations
PCT/AU2002/000910 WO2003008574A1 (en) 2001-07-18 2002-07-08 Mutations in ion channels

Publications (1)

Publication Number Publication Date
DE60222422D1 true DE60222422D1 (de) 2007-10-25

Family

ID=27158306

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60222422T Expired - Lifetime DE60222422D1 (de) 2001-07-18 2002-07-08 Mutationen in ionenkanälen

Country Status (9)

Country Link
US (2) US20050074764A1 (de)
EP (2) EP1407013B1 (de)
JP (1) JP2005501536A (de)
AT (1) ATE373089T1 (de)
AU (1) AU2002318972B8 (de)
CA (1) CA2454073C (de)
DE (1) DE60222422D1 (de)
NZ (2) NZ542048A (de)
WO (1) WO2003008574A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003904154A0 (en) * 2003-08-07 2003-08-21 Bionomics Limited Mutations in ion channels
US7709225B2 (en) * 2001-07-18 2010-05-04 Bionomics Limited Nucleic acids encoding mutations in sodium channels related to epilepsy
WO2003008574A1 (en) * 2001-07-18 2003-01-30 Bionomics Limited Mutations in ion channels
MXPA05001013A (es) 2002-07-30 2005-05-16 Wyeth Corp Formulaciones parentales que contienen un hidroxiester de rapamicina.
AU2003901425A0 (en) 2003-03-27 2003-04-10 Bionomics Limited A diagnostic method for epilepsy
AU2004263548B2 (en) * 2003-08-07 2007-09-13 Bionomics Limited Mutations in ion channels
JP2007537712A (ja) * 2003-10-13 2007-12-27 バイオノミックス リミテッド 新生児てんかん症候群または乳児てんかん症候群についての診断方法
JP2008524999A (ja) * 2004-12-24 2008-07-17 アレス トレーディング エス．エー． 精神障害を治療するための組成物及び方法
WO2006133508A1 (en) * 2005-06-16 2006-12-21 Bionomics Limited Methods of treatment, and diagnosis of epilepsy by detecting mutations in the scn1a gene
CN101960014B (zh) * 2008-02-01 2013-10-16 克罗莫塞尔公司 细胞系以及制备和使用其的方法
EP2770325A1 (de) 2013-02-26 2014-08-27 Institut du Cerveau et de la Moelle Epiniere-ICM Mutationen von DEPDC5 zur Diagnose von epileptischen Funktionsstörungen, Erkrankungen oder Leiden
JP7312451B2 (ja) 2018-01-26 2023-07-21 国立大学法人東海国立大学機構 受容体タンパク質を標的とする治療薬、検査薬、受容体タンパク質に結合する抗体、及び分子標的薬のスクリーニング方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016043A (en) * 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4971903A (en) * 1988-03-25 1990-11-20 Edward Hyman Pyrophosphate-based method and apparatus for sequencing nucleic acids
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
NO175199C (no) 1991-12-05 1994-09-14 Kvaerner Fjellstrand As Flerskrogfartöy
AU701228B2 (en) * 1995-06-28 1999-01-21 University Of Bonn Diagnostic and treatment methods relating to Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE)
US5646040A (en) 1995-06-30 1997-07-08 Millennium Pharmaceutical, Inc. Mammalian tub gene
US6331614B1 (en) * 1998-12-23 2001-12-18 Myriad Genetics, Inc. Human CDC14A gene
DE1252330T1 (de) * 1999-11-26 2003-11-27 Univ Montreal Mcgill Loci der idiopathischen epilepsie, mutationen derselben und verfahren zu deren verwendung zur feststellung, prognose und behandlung von epilepsie
US6703439B2 (en) * 2000-02-09 2004-03-09 Mitsui Chemicals, Inc. Polyolefin resin composition and polyolefin film prepared from the same
AUPQ749100A0 (en) 2000-05-12 2000-06-08 Bionomics Limited New epilespy gene
WO2001098486A1 (en) 2000-06-20 2001-12-27 Bionomics Limited Mutation associated with epilepsy
AUPQ882600A0 (en) 2000-07-18 2000-08-10 Bionomics Limited Mutations in ion channels
US6661614B2 (en) * 2000-09-27 2003-12-09 Seagate Technology Llc Magnetless actuator for disc drive
AUPR220300A0 (en) * 2000-12-20 2001-01-25 Bionomics Limited New epilepsy gene
AUPR492201A0 (en) 2001-05-10 2001-06-07 Bionomics Limited Novel mutation
WO2003008574A1 (en) 2001-07-18 2003-01-30 Bionomics Limited Mutations in ion channels
US7709225B2 (en) * 2001-07-18 2010-05-04 Bionomics Limited Nucleic acids encoding mutations in sodium channels related to epilepsy
US7282336B2 (en) * 2001-07-18 2007-10-16 Bionomics Limited Method of diagnosing epilepsy
AU2003904154A0 (en) 2003-08-07 2003-08-21 Bionomics Limited Mutations in ion channels
US20030157525A1 (en) * 2001-11-26 2003-08-21 Mintier Gabriel A. Novel human G-protein coupled receptor, HGPRBMY31, and variants and methods of use thereof
AU2003901425A0 (en) * 2003-03-27 2003-04-10 Bionomics Limited A diagnostic method for epilepsy
WO2006133508A1 (en) * 2005-06-16 2006-12-21 Bionomics Limited Methods of treatment, and diagnosis of epilepsy by detecting mutations in the scn1a gene

Also Published As

Publication number Publication date
CA2454073C (en) 2012-08-28
EP1852505A1 (de) 2007-11-07
AU2002318972B8 (en) 2007-08-09
JP2005501536A (ja) 2005-01-20
NZ530258A (en) 2006-01-27
EP1407013A4 (de) 2005-06-22
ATE373089T1 (de) 2007-09-15
AU2002318972B2 (en) 2007-03-08
WO2003008574A1 (en) 2003-01-30
EP1407013A1 (de) 2004-04-14
US7989182B2 (en) 2011-08-02
AU2002318972A1 (en) 2003-03-03
CA2454073A1 (en) 2003-01-30
NZ542048A (en) 2008-04-30
EP1852505B1 (de) 2010-03-31
US20100136623A1 (en) 2010-06-03
EP1407013B1 (de) 2007-09-12
US20050074764A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
ATE373089T1 (de) Mutationen in ionenkanälen
ZA200703433B (en) Identification of a JAK2 mutation in polycythemia vera
HK1131744A1 (en) Toll like receptor 3 antagonists, methods and uses toll
AR036160A1 (es) Regulacion de las vias metabolicas lipidicas en las plantas, mediante transgenesis con sentido o antisentido de factores de transcripcion hap2, hap5 y hap3/lec1
TWI365610B (en) Systems and methods for scalably encoding and decoding data
PL2185686T3 (pl) Komórki dendrytyczne
AR015687A2 (es) Gen aislado que codifica acil transferasa
WO2005027710A3 (en) Methods for identifying subjects at risk of melanoma and treatments thereof
DE602004009932D1 (de) Netzwerkgerät, System und Verfahren zur Authentifizierung
ATE412751T1 (de) Menschliche tak1 und für diese kodierende dna
WO2006046994A3 (en) Klf6 alternative splice forms and a germline klf6 dna polymorphism associated with increased cancer risk
EE200100234A (et) PRV-1-geen ja selle kasutamine
ATE318933T1 (de) Nukleinsäurefragmente zur identifizierung von dechlorierenden bakterien
SG158098A1 (en) Toll like receptor 3 antagonists, methods and uses
DE60226244D1 (de) Il-4 rezeptor sequenzvarianten, die mit typ i diabetes assoziiert sind
DE60329931D1 (de) Fprl1-liganden und deren verwendung
DE69930370D1 (de) Testisspezifische, menschliche proteinase, svph1-8
DE602005018326D1 (de) Für orotat-transporter codierende markergene
DK1470228T3 (da) Detektion af mutationer
ATE408686T1 (de) Chondrosarcom-assoziierte gene
WO2003025225A3 (en) Pthr1 gene polymorphisms
ATE517181T1 (de) Rekombinante carboxypeptidase b
UY27053A1 (es) Polimorfismos de nucleótidos simples humanos
Driscoll et al. Response from driscoll and colleagues
WO2005031341A3 (en) Methods for predicting development of insulin resistance

Legal Events

Date Code Title Description
8332 No legal effect for de